Interim results of ALLIANCE, the first head-to-head trial comparing two different tenofovir-containing antiretroviral regimens for the treatment of HIV and hepatitis B co-infection, demonstrate the superiority of bictegravir/emtricitabine/tenofovir alafenamide over dolutegravir plus tenofovir disoproxil fumarate , researchers reported here at the 24th International AIDS Conference .
The ongoing phase 3, multi-country study has 48-week results for 243 participants, who were HIV/HBV coinfected and treatment naïve. All subjects received three pills of ART per day, with blinded randomization to . The primary endpoints at 48 weeks were proportion of participants with HIV-1 RNA < 50 copies/mL and plasma HBV DNA < 29 IU/mL.
No participant developed treatment-emergent HIV-1 drug resistance while on B/F/TAF, and there were few study-drug related AEs or discontinuations, she reported. “The lower response rate of the TDF group is still poorly understood,” agreed Avihingsanon, emphasizing that “HBV and HIV/HBV are not the same, and TDF and TAF are also different. TAF has slightly more drug-drug interactions than TDF. I guess its end product in the liver might be higher. What is exciting to me is that there was such a high rate of HBsAg loss and HBs seroconversion in HIV/HBV coinfection, which is totally different from HBV monoinfection .
United States Latest News, United States Headlines
Similar News:You can also read news stories similar to this one that we have collected from other news sources.
Source: abc13houston - 🏆 255. / 63 Read more »
Source: abc7newsbayarea - 🏆 529. / 51 Read more »
Source: 6abc - 🏆 250. / 63 Read more »
Source: sfexaminer - 🏆 236. / 63 Read more »
Source: cleveland19news - 🏆 70. / 68 Read more »
Source: CNBC - 🏆 12. / 72 Read more »